Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

Overview of attention for article published in British Journal of Cancer, January 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 5 tweeters

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 34 Mendeley

Summary Twitter Dimensions citations

So far, Altmetric has seen 5 tweets from 5 users, with an upper bound of 13,075 followers.

📣 Results from the CirCe01 trial on the clinical utility of circulating tumour cell-based monitoring of late-line #chemotherapy for metastatic #BreastCancer by Bidard et al. are out now: https://t.co/SNIQvb5p4T @LucCabel1

01 Mar 2021

Reply Retweet Favourite

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial https://t.co/iIdygoFUyT

21 Jan 2021

Reply Retweet Favourite

RT @OncoPublisher: Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the…

21 Jan 2021

Reply Retweet Favourite

RT @OncoPublisher: Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the…

21 Jan 2021

Reply Retweet Favourite

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial #Oncology #MedTwitter #MedEd https://t.co/LWVjIvrwfX

21 Jan 2021

Reply Retweet Favourite